Download PDF
Semin Thromb Hemost 2011; 37(5): 595-601
DOI: 10.1055/s-0031-1281048
© Thieme Medical Publishers

Epidemiology, Diagnosis, and Management of von Willebrand Disease in India

Kanjaksha Ghosh1 , Shrimati Shetty1
  • 1National Institute of Immunohaematology (ICMR), KEM Hospital, Parel, Mumbai, India
Further Information

Publication History

Publication Date:
18 November 2011 (online)

    Permissions and Reprints

ABSTRACT

von Willebrand disease (VWD) in all developing countries including India is considered a rare coagulation disorder, contrary to many reports from Western countries. Prevalence data based on hospital referrals identifies type 3 VWD as the most common subtype followed by type 1 and type 2. Approximately 60 to 70% cases of type 3 VWD are reportedly born of consanguineous marriages. The discriminatory diagnostic tests mainly include assays for factor (F)VIII:C and ristocetin-induced platelet agglutination and von Willebrand factor (VWF) antigen either by immunoelectrophoresis or by enzyme-linked immunosorbent assay. VWD-type assisting tests like VWF collagen binding, VWF ristocetin cofactor assay, VWF-FVIII binding assay, and multimer analysis are occasionally used but not routinely applied in many laboratories. Among women, menorrhagia is an important presenting manifestation. Except for a handful of centers mainly in metropolitan cities, most laboratories in the remote parts of the country have no facilities for VWD-related investigations, resulting in occasional misdiagnoses of VWD as hemophilia A. Genetic diagnosis is being offered in two or three centers using the indirect linkage method in type 3 VWD, and efforts are continuing to implementing a direct mutation detection technique for routine practice in a few laboratories. Depending on the subtype or the severity of VWD, desmopressin, cryoprecipitate, fresh-frozen plasma, and factor VIII/VWF concentrates are used for management. Antifibrinolytic agents like epsilon-aminocaproic acid and tranexamic acid are widely used as an adjuvant therapy. In women with menorrhagia, oral contraceptives as a supplementary treatment are also being widely advocated to reduce bleeding. Products like danazol, ethenyl estradiol, thalidomide, and atorvastatin have been used in individual patients; acquired VWD associated with hypothyroidism has been managed successfully with thyroid hormone treatment. Both minor and major surgical procedures are performed in a few centers with judicious use of cryoprecipitate or FVIII concentrate containing VWF along with other supplementary therapeutic products to achieve adequate hemostasis. Awareness about the disease, establishment of the comprehensive coagulation laboratory, and treatment centers will be successful in increasing diagnosis of VWD and consequently better management of affected patients. This is likely to tilt the ratios of different VWD types, and VWD is likely to emerge as the most common of all coagulation disorders in the near future.

KEYWORDS

von Willebrand disease - diagnosis - management - epidemiology - India

REFERENCES

  • 1 Sadler JE, Mannucci PM, Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease.  Thromb Haemost. 2000;  84 (2) 160-174
    Google Scholar
  • 2 Mehta BC, Agarwal MB. Inherited coagulation disorders in India.  Indian J Pediatr. 1981;  48 (393) 525-531
    Google Scholar
  • 3 Kumar S, Kishore R, Gupta V, Jain M, Shukla J. Prevalence and spectrum of von Willebrand disease in Eastern Uttar Pradesh.  Indian J Pathol Microbiol. 2010;  53 (3) 486-489
    Google Scholar
  • 4 Ahmad F, Kannan M, Ranjan R, Bajaj J, Choudhary VP, Saxena R. Inherited platelet function disorders versus other inherited bleeding disorders: an Indian overview.  Thromb Res. 2008;  121 (6) 835-841
    Google Scholar
  • 5 Trasi S, Shetty S, Ghosh K, Mohanty D. Prevalence and spectrum of von Willebrand disease from western India.  Indian J Med Res. 2005;  121 (5) 653-658
    Google Scholar
  • 6 Srivastava A, Rodeghiero F. Epidemiology of von Willebrand disease in developing countries.  Semin Thromb Hemost. 2005;  31 (5) 569-576
    Google Scholar
  • 7 Mehta BC, Agarwal MB. Inherited disorders of coagulation in India.  The Ind J Paediatrics. 1981;  48 525-531
    Google Scholar
  • 8 Chandy M Indian Council for Medical Research ed.. Collaborative Study on Haemophilia: An ICMR Task Force Project. New Delhi, India: ICMR; 1990
    Google Scholar
  • 9 Cabrera ME, Artigas CG, Páez E et al. von Willebrand's disease in the IX Region of Chile.  Rev Med Chil. 1989;  117 (4) 423-430
    Google Scholar
  • 10 Diez-Ewald M, Vizcaíno G, Arteaga-Vizcaíno M, Fernández N, Weir-Medina J, Gómez O. Epidemiology of von Willebrand's disease in the state of Zulia, Venezuela.  Invest Clin. 1991;  32 (4) 187-199
    Google Scholar
  • 11 Karimi M, Yarmohammadi H, Ardeshiri R, Yarmohammadi H. Inherited coagulation disorders in southern Iran.  Haemophilia. 2002;  8 (6) 740-744
    Google Scholar
  • 12 Islam SI, Quadri MI. Spectrum of hereditary coagulation factor deficiencies in eastern province, Saudi Arabia.  East Mediterr Health J. 1999;  5 (6) 1188-1195
    Google Scholar
  • 13 Gupta PK, Ahmed RP, Sazawal S, Choudhry VP, Saxena R. Relatively high frequency of VWD types 3 and 2 in a cohort of Indian patients: the role of multimeric analysis.  J Thromb Haemost. 2005;  3 (6) 1321-1322
    Google Scholar
  • 14 Ghosh K, Trasi S, Shetty S, Mohanty D. Use of a new enzyme-linked immunosorbent assay for the detection of type 2N von Willebrand disease and its prevalence in an Indian population.  Blood Coagul Fibrinolysis. 2006;  17 (1) 7-11
    Google Scholar
  • 15 Giangrande PL, Black C. World Federation of Haemophilia programs in developing countries.  Semin Thromb Hemost. 2005;  31 (5) 555-560
    Google Scholar
  • 16 Edlund M, Blombäck M, von Schoultz B, Andersson O. On the value of menorrhagia as a predictor for coagulation disorders.  Am J Hematol. 1996;  53 (4) 234-238
    Google Scholar
  • 17 Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia.  Lancet. 1998;  351 (9101) 485-489
    Google Scholar
  • 18 Kouides P, Phatak P, Sham R et al. The prevalence of subnormal von Willebrand factor levels in menorrhagia patients in Rochester, NY: final analysis.  Haemophilia. 2000;  6 240-247
    Google Scholar
  • 19 Goodman-Gruen D, Hollenbach K. The prevalence of von Willebrand disease in women with abnormal uterine bleeding.  J Womens Health Gend Based Med. 2001;  10 (7) 677-680
    Google Scholar
  • 20 Saxena R, Gupta M, Gupta PK, Kashyap R, Choudhry VP, Bhargava M. Inherited bleeding disorders in Indian women with menorrhagia.  Haemophilia. 2003;  9 (2) 193-196
    Google Scholar
  • 21 Trasi SA, Pathare AV, Shetty SD, Ghosh K, Salvi V, Mohanty D. The spectrum of bleeding disorders in women with menorrhagia: a report from Western India.  Ann Hematol. 2005;  84 (5) 339-342
    Google Scholar
  • 22 Trasi S, Mohanty D, Pathare A, Shetty S, Ghosh K. von Willebrand factor 1 and factor 2 alleles (intron 40) are suitable markers for carrier detection in von Willebrand disease families in the Indian population.  Acta Haematol. 2006;  115 (1–2) 64-67
    Google Scholar
  • 23 Gupta PK, Kannan M, Saxena R. Carrier detection in severe von Willebrand's disease.  Ann Hematol. 2004;  83 (10) 625-627
    Google Scholar
  • 24 Trasi S, Mohanty D, Shetty S, Ghosh K. Prenatal diagnosis of von Willebrand disease in a family.  Natl Med J India. 2005;  18 (4) 187-188
    Google Scholar
  • 25 Shetty S, Ghosh K. Robustness of factor assays following cordocentesis in the prenatal diagnosis of haemophilia and other bleeding disorders.  Haemophilia. 2007;  13 (2) 172-177
    Google Scholar
  • 26 Gupta PK, Saxena R, Adamtziki E et al. Genetic defects in von Willebrand disease type 3 in Indian and Greek patients.  Blood Cells Mol Dis. 2008;  41 (2) 219-222
    Google Scholar
  • 27 Baronciani L, Cozzi G, Canciani MT et al. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients.  Blood Cells Mol Dis. 2003;  30 (3) 264-270
    Google Scholar
  • 28 Gupta PK, Adamtziki E, Budde U et al. Gene conversions are a common cause of von Willebrand disease.  Br J Haematol. 2005;  130 (5) 752-758
    Google Scholar
  • 29 Kasatkar P, Shetty S, Ghosh K. VWF pseudogene: mimics, masks and spoils.  Clin Chim Acta. 2010;  411 (7-8) 607-609
    Google Scholar
  • 30 Nomikou E, Tsevrenis V, Gafou A, Bellia M, Theodossiades G. Type IIb von Willebrand disease with angiodysplasias and refractory gastrointestinal bleeding successfully treated with thalidomide.  Haemophilia. 2009;  15 (6) 1340-1342
    Google Scholar
  • 31 Sohal M, Laffan M. von Willebrand disease and angiodysplasia responding to atorvastatin.  Br J Haematol. 2008;  142 (2) 308-309
    Google Scholar
  • 32 Viswabandya A, Mathews V, George B et al. Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI.  Haemophilia. 2008;  14 (4) 763-767
    Google Scholar
  • 33 Mathews V, Srivastava A, Nair SC, Chandy M. Haemostasis with cryoprecipitate in patients undergoing surgery for severe von Willebrand disease.  Natl Med J India. 2000;  13 (4) 188-190
    Google Scholar
  • 34 Shanthala Devi AM, Sitalakshmi S, Anuradha S. Profile of inherited bleeding disorders in a teaching hospital.  Ind J Hematol Blood Transf. 1999;  17 17-19
    Google Scholar
  • 35 Mohanty D, Ghosh K, Das K. Inherited disorders of blood coagulation in North Western India.  Thromb Haemost. 1983;  50 (Suppl 1) 272 Abstract 0853
    Google Scholar

Kanjaksha GhoshM.D. 

National Institute of Immunohaematology (ICMR)

KEM Hospital, Parel, Mumbai, India

Email: kanjakshaghosh@hotmail.com

      >